ArticleScience translational medicine2024
SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma.
Abstract read
In one paragraph
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer.Cancer research communications · 2026Article
- Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1Pharmaceuticals (Basel, Switzerland) · 2026Article
- Amino acid metabolic reprogramming: future prospects for cholangiocarcinoma therapy.Cell death discovery · 2026Review
- Clinical significance and functional characterization of RRN3 in gastric cancer: insights from pan-cancer analysis and experimental validation.Frontiers in oncology · 2026Article
- mTOR signaling in cholangiocarcinoma: mechanistic insights and therapeutic opportunities.Frontiers in pharmacology · 2026Review
- Immune-related long noncoding RNAs in predicting the prognosis and immune landscape of intrahepatic cholangiocarcinoma: a bioinformatics analysis with experimental verification.Translational cancer research · 2025Article
- Review
- HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity.Nature communications · 2025Article
- IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies.Current oncology (Toronto, Ont.) · 2025Review
- METTL3-mediated m6A methylation on lncRNA H19 inhibits intrahepatic cholangiocarcinoma progression through PPARγ downregulation.International journal of biological sciences · 2025Article
- Applications of 3D models in cholangiocarcinoma.Frontiers in oncology · 2025Review
- Patient-derived organoids in non-small cell lung cancer: advances in drug sensitivity testing.Frontiers in pharmacology · 2025Review
- The Mechanism of Action of the Active Ingredients ofViruses · 2024Article
- Dual Inhibition of PI3 Kinase and MAP Kinase Signaling Pathways in Intrahepatic Cholangiocellular Carcinoma Cell Lines Leads to Proliferation Arrest but Not Apoptosis.Current issues in molecular biology · 2024Article
- Organoids and spheroids: advancedFrontiers in cell and developmental biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Iris S LukHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0008-3103-8040
Caroline M BridgwaterHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-3016-7242
Angela YuHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Liberalis D BoilaHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-5672-6607
Mariana Yáñez-BartoloméPreclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0000-0002-1218-7875
Aaron E LampanoHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-2354-599X
Taylor S HulahanHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-8034-9445
Myriam BoukhaliMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0001-9607-8862
Meena KathiresanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.
Teresa MacarullaPreclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Heidi L KenersonDepartment of Surgery, University of Washington, Seattle, WA 98195, USA.
Naomi YamamotoHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-0641-6547
David SokolovHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-6774-4133
Ian A EngstromHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-7843-6272
Lucas B SullivanHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-6745-8222
Paul D LampeHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-1399-2761
Jonathan A CooperBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-8626-7827
Raymond S YeungDepartment of Surgery, University of Washington, Seattle, WA 98195, USA.
Tian V TianPreclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Wilhelm HaasMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0001-8225-9099
Supriya K SahaHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Sita KugelHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-7202-187X
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MTraining in Cellular & Molecular BiologyT32GM136534 · NIGMS · UNIVERSITY OF WASHINGTON · PI Andrew Atwell Oberst, LARRY S ZWEIFEL · 2021 to 2026
$5.8MExploring the epigenetic control of pancreatic cancer subtypesR37CA241472 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KUGEL, SITA · 2019 to 2025
$2.8MExploring novel SRC-regulated pathways in IDH mutant intrahepatic cholangiocarcinomaR01CA255015 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KUGEL, SITA · 2021 to 2025
$2.0MNovel targeted therapies for isocitrate dehydrogenase mutantcholangiocarcinomaK08CA194268 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SAHA, SUPRIYA K · 2015 to 2019
$866kEvaluating Novel Targeted Therapies in Cholangiocarcinoma Using Tumor Slice CulturesR21CA231486 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KUGEL, SITA · 2019 to 2020
$430kNCI NIH HHS K08 CA194268NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA255015NCI NIH HHS R21 CA231486NCI NIH HHS R37 CA241472NIGMS NIH HHS T32 GM136534
Abstract
Intrahepatic cholangiocarcinoma (ICC) is an aggressive bile duct malignancy that frequently exhibits isocitrate dehydrogenase (
Indexed as
Adaptor Proteins, Signal TransducingCholangiocarcinomaDasatinibIsocitrate DehydrogenaseMutationsrc-Family KinasesAnimalsBile Duct NeoplasmsCell Adhesion MoleculesCell Line, TumorCell ProliferationGuanylate KinasesHumansMicePhosphorylationProtein Phosphatase 2Adaptor Proteins, Signal TransducingCell Adhesion MoleculesDasatinibGuanylate KinasesIsocitrate DehydrogenaseMAGI1 protein, humanProtein Phosphatase 2Ribosomal Protein S6 Kinases, 70-kDasrc-Family Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.